Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference


Business Wire | Aug 5, 2020 07:01AM EDT

Castle Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference

Aug. 05, 2020

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Aug. 05, 2020--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020, at 4:30 p.m. Eastern time.

A live audio webcast of the company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/news-events/events-presentations. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx(r)-Melanoma, DecisionDx(r)-CMSeq; www.SkinMelanoma.com) and uveal melanoma (DecisionDx(r)-UM, DecisionDx(r)-PRAME and DecisionDx(r)-UMSeq; www.MyUvealMelanoma.com), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005231/en/

CONTACT: Media and Investor Contact: Camilla Zuckero 832-835-5158 czuckero@castlebiosciences.com






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC